Xencor, Inc Increase (Decrease) in Other Noncurrent Assets
Xencor, Inc (XNCR) reported Increase (Decrease) in Other Noncurrent Assets of $46.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2020-02-25
- Xencor, Inc increase (decrease) in other noncurrent assets for the quarter ending 2014-03-31 was -$50.00K.
- Xencor, Inc increase (decrease) in other noncurrent assets for fiscal 2018 was $46.00K, a 71.43% decline from fiscal 2017.
- Xencor, Inc increase (decrease) in other noncurrent assets for fiscal 2017 was $161.00K, a 302.50% increase from fiscal 2016.
- Xencor, Inc increase (decrease) in other noncurrent assets for fiscal 2016 was $40.00K, a 1233.33% increase from fiscal 2015.
- Xencor, Inc increase (decrease) in other noncurrent assets for fiscal 2015 was $3.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|
| 2018-12-31 | $46.00K 10-K · filed 2020-02-25 | ||
| 2017-12-31 | $161.00K 10-K · filed 2020-02-25 | ||
| 2016-12-31 | $40.00K 10-K · filed 2019-02-26 | ||
| 2015-12-31 | $3.00K 10-K · filed 2018-02-28 | ||
| 2015-06-30 | $4.00K 10-Q · filed 2015-08-05 | ||
| 2014-12-31 | -$41.00K 10-K · filed 2017-03-01 | ||
| 2014-03-31 | -$50.00K 10-Q · filed 2015-05-05 | ||
| 2013-12-31 | $20.00K 10-K · filed 2016-03-08 | ||
| 2012-12-31 | -$15.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |